Piperine
HerbalPreclinicalAlso known as: Bioperine, Black pepper extract, 1-Piperoylpiperidine, (E,E)-Piperine
Piperine is the pungent alkaloid of black pepper (Piper nigrum) — the compound responsible for pepper's characteristic heat and aroma — and it has become one of the single most important adjuvants in the modern supplement industry not because of any direct clinical effect of its own, but because of its notable ability to increase the oral bioavailability of dozens of co-administered drugs, herbs, and nutrients. At practical supplement doses (typically 5-20mg as standardized Bioperine extract), piperine is the reason your curcumin capsule is paired with "black pepper extract," the reason your quercetin is labeled "with Bioperine," and the reason so many stack products reach meaningful plasma levels of otherwise poorly-absorbed polyphenols.
Overview
At A Glance
Piperine acts primarily as a broad-spectrum inhibitor of drug metabolism and efflux — it is not a classical agonist at any receptor, and its downstream effects on co-administered compounds flow entirely from this enzyme- and transporter-inhibition profile. The mechanistic picture…
Mechanism of Action
Piperine acts primarily as a broad-spectrum inhibitor of drug metabolism and efflux — it is not a classical agonist at any receptor, and its downstream effects on co-administered compounds flow entirely from this enzyme- and transporter-inhibition profile. The mechanistic picture has three pillars — CYP450 inhibition, P-glycoprotein inhibition, and UGT inhibition — plus several ancillary effects on brush-border membrane dynamics, intestinal blood flow, and minor direct receptor-level interactions.
CYP3A4 inhibition — the dominant pharmacokinetic interaction: CYP3A4 is the single most abundant and most promiscuous cytochrome P450 enzyme in human liver and intestinal epithelium, handling first-pass metabolism of roughly 50% of all clinically used drugs. Bhardwaj et al. 2002 (J Pharmacol Exp Ther) — the definitive early human CYP3A4 study — showed that oral piperine 20mg for 7-14 days significantly reduced CYP3A4-mediated metabolism of midazolam, a classic CYP3A4 probe substrate, raising midazolam AUC by roughly 2-fold. Piperine appears to act as a mixed mechanism-based (suicide) and reversible inhibitor of CYP3A4 — it binds the enzyme's active site, and with the methylenedioxyphenyl (MDP) moiety it can be metabolized to a carbene intermediate that forms a stable complex with the heme iron of CYP3A4, producing lasting enzyme inactivation that persists until new enzyme is synthesized. This is analogous to grapefruit furanocoumarins (bergamottin), which also form carbene adducts with intestinal CYP3A4. Practical consequence: piperine's CYP3A4 inhibition is not just acute — it can last 24-48 hours after a single dose as inactivated enzyme is gradually replaced. Volak et al. 2013 (Drug Metab Dispos) confirmed these findings in a controlled human phenotyping study — a single 20mg piperine dose produced measurable CYP3A4 inhibition that outlasted plasma piperine.
P-glycoprotein (P-gp, ABCB1) inhibition — the efflux-pump mechanism: P-glycoprotein is an ATP-dependent efflux transporter expressed on the apical (luminal) surface of intestinal enterocytes, the bile canalicular membrane of hepatocytes, the blood-brain barrier, and the blood-testis and placental barriers. Its physiological function is to pump xenobiotics back out of cells — out of gut enterocytes into the lumen, out of hepatocytes into bile, out of brain endothelial cells back into blood — limiting systemic absorption and tissue penetration of a huge range of substrates. Han et al. 2011 (Drug Metab Dispos) demonstrated in cell culture and rodent models that piperine at micromolar concentrations significantly inhibits P-gp-mediated drug efflux, raising intestinal absorption and brain uptake of classic P-gp substrates (digoxin, rhodamine-123, various anticancer drugs). The inhibition is non-competitive and reasonably potent — IC50 values in the low micromolar range — and contributes substantially to piperine's enhancement of curcumin, EGCG, and similar P-gp substrate polyphenols. Clinical consequence: compounds whose oral absorption is limited by P-gp efflux (including many statins, immunosuppressants, HIV protease inhibitors, and anticancer drugs) will have raised plasma levels in the presence of piperine.
UDP-glucuronosyltransferase (UGT) inhibition — the Phase II conjugation mechanism: Many polyphenols and flavonoids — curcumin, quercetin, fisetin, resveratrol, EGCG — are rapidly glucuronidated in intestinal enterocytes and hepatocytes by UGT1A and UGT2B enzymes, producing water-soluble glucuronide conjugates that are rapidly excreted in bile and urine. The glucuronide conjugates generally have reduced pharmacologic activity relative to the parent aglycone (there are exceptions), and the rapid Phase II conjugation is the main reason these compounds have dismal oral bioavailability — often <5% for curcumin, <10% for resveratrol, <20% for quercetin aglycone. Piperine inhibits UGT1A1, UGT1A3, UGT1A6, UGT1A9, and UGT2B7 at physiologically achievable concentrations. This is the mechanism that most directly explains the Shoba 1998 curcumin result (PMID: 9619120) — raising curcumin AUC ~20-fold by blocking the enzymes that would otherwise conjugate it into useless glucuronides before it can reach systemic circulation.
Sulfotransferase (SULT) inhibition: Piperine also weakly inhibits sulfotransferases, which are another Phase II conjugation pathway. This is less well-characterized quantitatively than UGT inhibition but contributes to the overall bioavailability-enhancement effect for sulfate-conjugated compounds.
Secondary CYP inhibitions: Piperine is a weaker but real inhibitor of CYP2D6 (handling ~25% of prescription drugs including many antidepressants, beta-blockers, opioids, antipsychotics), CYP1A2 (handling caffeine, theophylline, tacrine, melatonin, tizanidine), and CYP2C9 (handling warfarin, phenytoin, some NSAIDs). These interactions are less pronounced than the CYP3A4 effect but are relevant in polypharmacy contexts.
Brush-border membrane effects: Multiple rodent studies have shown that piperine alters the lipid composition and fluidity of intestinal brush-border membrane vesicles, increasing passive paracellular absorption of co-administered nutrients. This non-specific "leaky gut" effect at the enterocyte level contributes modestly to bioavailability enhancement for poorly-absorbed compounds. Whether this effect is clinically meaningful at normal supplement doses in humans is debated.
Thermogenic and metabolic direct effects: Piperine has been shown in rodent models to activate TRPV1 (transient receptor potential vanilloid 1) — the same receptor activated by capsaicin — producing mild thermogenic and metabolic activation. In human trials, a single 20mg dose of piperine has produced small but measurable increases in thermogenesis and energy expenditure, though the effect size is modest relative to capsaicin-containing products. Atal et al. 1985was an early mechanistic study documenting piperine's biochemical effects on hepatic drug metabolism and digestive enzyme activity in rodents, serving as a foundational reference for the subsequent bioavailability-enhancement literature.
Antidiarrheal effect: Piperine has documented antidiarrheal activity in rodent and clinical settings, likely mediated through TRPV1 activation and calcium-channel modulation in enteric neurons. Bajad et al. 2001characterized the mechanism in rodent models — piperine reduces castor oil-induced diarrhea and modulates intestinal transit time through peripheral neuronal pathways. This is not a major clinical use but is part of traditional Ayurvedic use of black pepper in trikatu formulations.
Anti-inflammatory and NF-κB modulation: In cell culture and rodent inflammation models, piperine reduces NF-κB-mediated inflammatory signaling, lowering production of TNF-α, IL-6, IL-1β, and COX-2. The concentrations required for these effects are generally higher than achieved at normal supplement doses, and the clinical relevance of piperine's direct anti-inflammatory effects in humans is uncertain. Most of the anti-inflammatory benefit attributed to "piperine" in human stacks is indirectly mediated — raising curcumin or quercetin bioavailability, which are the actual anti-inflammatory agents.
Neuroprotective and cognitive effects (speculative): Rodent studies have reported piperine effects on BDNF expression, monoamine oxidase (MAO) inhibition, and neurogenesis markers. These findings are preliminary, use rodent doses that are not clinically equivalent to human supplement doses, and have not been replicated in rigorous human trials. Claims about piperine as a standalone nootropic or antidepressant are premature.
Anti-adipogenic effect: Several rodent studies have reported that piperine inhibits adipogenic differentiation of preadipocytes and reduces fat accumulation in high-fat-diet-fed rodents, possibly through PPARγ modulation and adipocyte-specific gene regulation. Human trials showing this effect are limited, and the doses used in rodent studies (10-40 mg/kg) would correspond to much higher human doses than are typically used.
Pharmacokinetics of piperine itself: Piperine has moderate oral bioavailability (~40-50% in humans), reaches peak plasma concentrations in 1-2 hours, has a plasma half-life of ~3-6 hours, and is cleared primarily by hepatic metabolism (including — amusingly — some CYP3A4-mediated oxidation; piperine inhibits the same enzyme that partially metabolizes it). It is reasonably fat-soluble, achieves tissue distribution including CNS (it does cross the blood-brain barrier in detectable amounts), and is excreted primarily as conjugates in urine and feces.
Duration of CYP inhibition: Because a component of piperine's CYP3A4 inhibition is mechanism-based (suicide inhibition via MDP-derived carbene adduct to heme iron), enzyme activity recovery requires new protein synthesis, typically 24-48 hours for intestinal CYP3A4. This means that piperine taken once a day — or even intermittently — can sustain meaningful CYP3A4 inhibition across the dosing interval, which is relevant for drug-interaction risk assessment. You don't have to take piperine simultaneously with a drug for it to affect that drug's metabolism; same-day dosing can be sufficient.
The dose-response problem: Most clinical bioavailability-enhancement studies of piperine have used 5-20mg doses with co-administered substrate. Higher doses (40-80mg, as sometimes used in rodent studies) may produce more enzyme inhibition but also raise the risk of direct piperine effects (thermogenesis, GI irritation) and drug interactions with any concurrent prescription medication. The sweet spot for bioavailability enhancement without excessive direct or interaction effects is 5-20mg per dose, which is why that is the range on virtually every commercial Bioperine-containing product.
Overview
Piperine is the pungent alkaloid of black pepper (Piper nigrum) — the compound responsible for pepper's characteristic heat and aroma — and it has become one of the single most important adjuvants in the modern supplement industry not because of any direct clinical effect of its own, but because of its notable ability to increase the oral bioavailability of dozens of co-administered drugs, herbs, and nutrients. At practical supplement doses (typically 5-20mg as standardized Bioperine extract), piperine is the reason your curcumin capsule is paired with "black pepper extract," the reason your quercetin is labeled "with Bioperine," and the reason so many stack products reach meaningful plasma levels of otherwise poorly-absorbed polyphenols. Understanding piperine is, more than anything else, understanding why and when bioavailability enhancement matters — and, just as importantly, why that same mechanism creates real drug-interaction risk that most supplement labels understate.
Chemically, piperine is 1-piperoylpiperidine — an amide formed between piperic acid and the cyclic secondary amine piperidine, with an (E,E)-configured conjugated diene bridging a methylenedioxyphenyl (piperonyl) ring. It is a pale yellow crystalline solid, poorly water-soluble, reasonably fat-soluble, and present at roughly 3-9% by weight in dried whole black pepper berries and slightly higher in white pepper. Long black pepper (Piper longum) contains piperine plus a closely related alkaloid piplartine (piperlongumine) that has attracted independent attention as a senolytic and anticancer research tool — although that's a different molecule with a different risk profile, and the commercial "piperine" used in supplements is essentially always the Piper nigrum extract, standardized to ≥95% piperine in the case of the trademarked Bioperine product (Sabinsa Corporation, established 1996).
The single paper that made piperine famous in the supplement world is Shoba et al. 1998 (Planta Medica PMID: 9619120) — a small but landmark pharmacokinetic study showing that co-administration of 20mg piperine with 2g curcumin raised curcumin bioavailability by approximately 2000% in humans relative to curcumin alone. That single headline number — "2000 percent increase" — has been repeated in curcumin marketing copy for nearly three decades, and it is substantially true for oral curcumin specifically (curcumin is one of the worst-absorbed polyphenols ever commercialized; the ceiling is so low that even modest increases are dramatic in relative terms). What the original Shoba paper did not say, and what is often elided in marketing, is that the effect is compound-specific — piperine increases the bioavailability of some drugs/nutrients substantially, others modestly, and others not at all, depending on whether that compound's absorption is limited by Phase II conjugation, P-glycoprotein efflux, or CYP3A4 first-pass metabolism. Piperine inhibits all three; if a compound's absorption is limited by something else (e.g., poor intestinal dissolution, bile-acid-dependent micelle formation), piperine does nothing.
Mechanistically, piperine works by three main routes: (1) inhibition of hepatic and intestinal CYP3A4 (the most clinically important cytochrome P450 enzyme, handling ~50% of all prescribed drugs); (2) inhibition of P-glycoprotein (P-gp, ABCB1) — an ATP-dependent efflux pump that normally pushes xenobiotics back out of intestinal enterocytes and hepatocytes into the lumen and bile, dramatically limiting absorption and tissue penetration; (3) inhibition of UDP-glucuronosyltransferases (UGTs) — the Phase II conjugation enzymes that rapidly glucuronidate flavonoids and polyphenols (quercetin, curcumin, resveratrol, EGCG) into more water-soluble, rapidly-excreted conjugates. In addition, piperine weakly inhibits CYP2D6, CYP1A2, and sulfotransferases (SULTs), and it may increase intestinal blood flow and disrupt brush-border membrane lipid dynamics in ways that increase passive paracellular absorption. The combined net effect is that a drug or nutrient that would normally be rapidly conjugated, pumped back into the gut lumen, and cleared by first-pass hepatic metabolism instead reaches the systemic circulation at multiples of its unaided concentration.
Who uses it and why — the practical picture — breaks down roughly as follows. Most users never consciously add piperine: they get it embedded in formulated products. The majority of curcumin supplements on the US market include 5-10mg Bioperine. Most quercetin products include piperine. Many fisetin "senolytic" protocols include it. A growing number of resveratrol products include piperine despite the resveratrol literature actually showing that piperine raises resveratrol AUC by a more modest (but still meaningful) ~2-fold rather than 20-fold. Standalone piperine capsules (5-10mg, typically Bioperine-branded) are marketed as a "universal bioavailability booster" — to add to any stack where absorption is limiting. Traditional Ayurvedic and Unani medicine have used trikatu — a formula of black pepper, long pepper, and ginger — for millennia as a digestive and bioenhancer adjunct to herbal preparations; trikatu is essentially the pre-modern, empirical version of a Bioperine stack, and it works for the same pharmacological reasons.
Where piperine gets you into trouble is the mirror image of why it's useful. CYP3A4 is not a niche enzyme — it metabolizes roughly half of all prescription drugs. Statins (simvastatin, atorvastatin, lovastatin), calcium-channel blockers (amlodipine, felodipine, diltiazem), many benzodiazepines (midazolam, triazolam, alprazolam), most macrolide antibiotics, cyclosporine and tacrolimus (immunosuppressants used in transplant), many antihistamines, many anti-HIV protease inhibitors, many chemotherapy agents, warfarin partly, carbamazepine, and a long list of psychiatric medications all route through CYP3A4. Inhibiting CYP3A4 means raising plasma levels of every one of those drugs in a dose-dependent and often clinically meaningful way. The grapefruit-juice interaction familiar to most pharmacists is a CYP3A4 inhibition; piperine is a weaker but real version of the same effect. Most self-experimenters don't think of their "5mg black pepper extract" as a pharmacokinetic enhancer for their statin, calcium-channel blocker, or SSRI — but that's exactly what it is, and the dose-response is well-characterized in human studies (see Bhardwaj 2002, Volak 2013, Han 2011). This is the single most important safety consideration for piperine: it is not pharmacologically inert, and it should be considered a genuine drug-interaction modifier when any prescription medication metabolized by CYP3A4, P-gp, or UGT is in play.
Beyond bioavailability enhancement, piperine has a secondary literature of direct biological effects that range from the modest and plausible (mild thermogenic/metabolic activity, transient antidiarrheal effects, anti-inflammatory signaling in cell culture) to the speculative and preliminary (neuroprotection, anticancer adjuvant, melanogenesis modulation, adipogenesis inhibition). None of these direct effects are strong enough to justify piperine as a standalone therapeutic, and most of the cell-culture and rodent findings involve concentrations that are never achieved in human plasma at normal supplement doses. But the direct effects aren't zero, and in the thermogenesis and adipocyte-signaling contexts they may contribute modestly to metabolic stacks. The honest framing: piperine is a bioavailability enhancer first and a minor direct-effect compound second. If you're stacking it for curcumin, quercetin, resveratrol, EGCG, or fisetin absorption, you're on solid ground. If you're stacking it for its own metabolic or neuroprotective effects, the evidence is thin.
See also curcumin, quercetin, fisetin, ashwagandha, rhodiola-rosea, berberine, tulsi, and EGCG for the compounds most commonly paired with piperine in bioavailability-enhancement stacks. This is educational content and not medical advice — piperine is a real drug-interaction modifier and warrants physician-level guidance when any prescription medication is concurrent. The convenience of "a little black pepper extract" in a supplement stack should not obscure the fact that, mechanistically, it is operating on the same enzyme systems as grapefruit juice, St. John's wort, and many prescription pharmacokinetic modifiers.
Chemical Information
IUPAC Name
Not yet available
CAS Number
Not yet available
Molecular Formula
Not yet available
Molecular Mass
Not yet available
Chemical data is being compiled for this compound.
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Contraindications
Absolute contraindications:
Known hypersensitivity to piperine, black pepper, product excipients, or prior allergic reaction — discontinue if rash, swelling, respiratory symptoms, or systemic allergic symptoms occur.
Active organ transplantation on immunosuppressants (cyclosporine, tacrolimus, sirolimus, everolimus) — absolute contraindication. Piperine raises immunosuppressant levels via CYP3A4 and P-gp inhibition, potentially to toxic ranges, with serious consequences for allograft and patient safety. Discuss ANY supplement with transplant team; piperine specifically is high-risk.
Active chemotherapy with CYP3A4 or P-gp substrate drugs — generally contraindicated without oncologist approval. Piperine can alter chemotherapy drug exposure unpredictably, amplifying toxicity or reducing efficacy.
Concurrent treatment with narrow-therapeutic-index CYP3A4-sensitive drugs (warfarin, digoxin, phenytoin, carbamazepine, lithium, theophylline) — generally avoided without physician-directed monitoring. Piperine's pharmacokinetic enhancement can push these drugs into toxic ranges.
Active pregnancy — rodent reproductive-toxicity signals at high doses and amplified drug-interaction concerns argue against supplemental piperine in pregnancy. Culinary black pepper in food is fine; standardized piperine supplements should be avoided. Discuss with obstetrician.
Relative contraindications requiring medical guidance:
Concurrent use of CYP3A4-metabolized statins (simvastatin, atorvastatin, lovastatin) — piperine raises statin exposure and increases myopathy/rhabdomyolysis risk. Monitor for new muscle pain; baseline and follow-up CK measurement is reasonable. Rosuvastatin and pravastatin are less CYP3A4-dependent and carry lower interaction risk.
Concurrent calcium-channel blockers (amlodipine, felodipine, nifedipine, verapamil, diltiazem) — CYP3A4 substrates; piperine can raise levels and intensify hypotension. Monitor BP.
Concurrent benzodiazepines (midazolam, triazolam, alprazolam, diazepam) — CYP3A4 substrates; piperine can intensify sedation. Caution with driving/operating machinery.
Concurrent psychiatric medications — many SSRIs, SNRIs, TCAs, antipsychotics, and mood stabilizers are CYP2D6 or CYP3A4 substrates. Piperine can raise exposure and alter therapeutic effects or serotonergic load. Psychiatrist awareness is reasonable.
Concurrent HIV protease inhibitors, anti-HIV regimens — CYP3A4 substrate interactions can be complex and consequential. ID physician involvement required.
Concurrent anticoagulants (warfarin, direct oral anticoagulants) — warfarin is partly CYP3A4-metabolized; piperine can raise exposure and increase bleeding risk. INR monitoring warranted. Less data on DOACs but caution is reasonable.
Concurrent macrolide antibiotics, azole antifungals (erythromycin, clarithromycin, ketoconazole, itraconazole) — these are themselves CYP3A4 substrates and inhibitors; combining with piperine produces additive CYP3A4 inhibition affecting other concurrent medications.
Concurrent anticonvulsants (phenytoin, carbamazepine) — partly CYP3A4-metabolized; piperine can alter seizure control. Neurologist awareness.
Concurrent opioids (fentanyl, oxycodone, methadone, buprenorphine) — CYP3A4 substrates; piperine can intensify respiratory depression and sedation. Particular caution in opioid-naive users.
Concurrent anticancer agents — most chemotherapy drugs are CYP3A4 or P-gp substrates. Oncologist involvement required before any piperine use during active cancer treatment.
Concurrent digoxin — P-gp substrate with narrow therapeutic index; piperine can raise levels and produce toxicity. Monitor digoxin levels.
Pre-existing GERD, esophagitis, or peptic ulcer disease — piperine's TRPV1-mediated mucosal irritation may worsen symptoms. Use lower doses, take with food, or avoid.
Severe hepatic impairment — piperine metabolism is hepatic; amplified drug interactions and potential piperine accumulation in advanced liver disease argue for caution or avoidance.
Surgery planned within 2 weeks — discontinue piperine to allow CYP3A4 recovery and simplify peri-operative medication management.
Pregnancy-specific considerations: Supplemental piperine not recommended; dietary black pepper from food is fine. Rodent studies suggest reproductive-toxicity concerns at doses much higher than typical supplement use, but the drug-interaction amplification during pregnancy (when hormonal and metabolic changes already alter drug disposition) is the more practical concern.
Breastfeeding: Limited safety data for supplemental piperine during lactation. Dietary black pepper is fine. Avoid supplemental piperine without lactation consultant/pediatrician input.
Pediatric use: Not recommended under 18 years for standardized supplemental piperine. Culinary black pepper in food is universally fine. No pediatric clinical data for supplemental forms, and the full adult drug-interaction profile applies.
Situations warranting medical consultation before use:
- Any prescription medication — particularly CYP3A4, CYP2D6, P-gp, UGT substrates. Pharmacist medication review is reasonable.
- Transplant recipient — immunosuppressant interaction is high-risk.
- Active chemotherapy or HIV antiretroviral therapy — oncologist/ID approval required.
- Narrow-therapeutic-index drugs (warfarin, digoxin, phenytoin, carbamazepine, lithium) — physician involvement required.
- Pregnancy or breastfeeding — default to dietary black pepper only.
- Elective surgery planned — discontinue 2 weeks before.
- Severe liver or kidney disease — physician input.
- Pre-existing severe GI disease — use lower doses or avoid.
New drug-interaction-suggestive symptoms on piperine — unexplained intensification of prescription medication effects (new muscle pain on statins, altered anticoagulation, unusual sedation, new side effects from stable prescription regimens) — warrants reassessment and physician consultation. Piperine is a real pharmacokinetic modifier; apparent "side effects" in a polypharmacy context are often interaction-driven rather than direct piperine effects.
Legal and regulatory status: Piperine (Bioperine) is a dietary supplement and food ingredient in the US, Canada, UK, EU, Australia, and most countries — legally available without prescription. Culinary black pepper is universally legal. Not a controlled substance; WADA permits piperine-containing supplements in competitive sport.
Quality variability concern: Unstandardized "black pepper extract" products vary widely in actual piperine content, meaning clinical effects also vary. Prefer Bioperine (Sabinsa) or other ≥95% standardized products with third-party testing.
Not medical advice: This content is educational. Specific use decisions — particularly in polypharmacy contexts, pregnancy, liver or kidney disease, immunosuppression, active cancer treatment, or with any narrow-therapeutic-index prescription medication — warrant physician-level guidance tailored to individual circumstances. Piperine is a real pharmacokinetic modifier, not an inert supplement.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
No listings found for Piperine.
Related Compounds
View AllBeta-Sitosterol
HerbalPreclinicalBeta-sitosterol (β-sitosterol) is the most abundant plant sterol in human diets and nature, structurally similar to cholesterol but with an ethyl group addition at C-24 position, making it a phytosterol rather than a zoosterol.
Boswellia
HerbalPreclinicalBoswellia — the aromatic gum resin of the tree Boswellia serrata, known in Ayurvedic tradition as Shallaki or Salai guggul and in English as Indian frankincense — is one of the best-characterized non-NSAID anti-inflammatory botanicals in the modern clinical literature, and one of the few whose mechanism is sufficiently well-understood at the molecular level to justify most of its clinical positioning.
Comfrey
HerbalPreclinicalComfrey (Symphytum officinale) is one of the most mechanistically interesting — and simultaneously one of the most legally and toxicologically constrained — herbs in traditional European medicine.
Grape Seed Extract
HerbalPreclinicalGrape Seed Extract (GSE) — the lipid-soluble polyphenol-rich concentrate derived from the seeds of the common wine grape (Vitis vinifera, family Vitaceae) — is one of the most widely sold, most extensively researched, and most commercially heterogeneous botanical antioxidant products in the global supplement market.
Maitake
HerbalPreclinicalMaitake (Grifola frondosa) is a large, fan-shaped polypore fungus native to the temperate hardwood forests of Japan, China, Korea, and parts of northeastern North America and Europe.
Pygeum
HerbalPreclinicalPygeum (Prunus africana, formerly classified as Pygeum africanum) is a lipophilic bark extract derived from the African cherry tree — a large, slow-growing evergreen hardwood species native to the mountainous forests of sub-Saharan Africa, from Cameroon and Kenya through Uganda, Tanzania, Ethiopia, Madagascar, and south to South Africa.
View Full Dosage Guide →
Protocols, calculator & safety for Piperine
Research Score
2234 PubMed studies
Quality Indicators
Data Completeness
63%Research Credibility
Well-researched compound
Quick Facts
Trial Phase
Preclinical
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
Does piperine actually increase curcumin absorption by 2000%?
Yes — that headline number comes from Shoba et al. 1998 (Planta Medica PMID: 9619120), a small but landmark human pharmacokinetic study showing that 20mg piperine co-administered with 2g curcumin raised curcumin bioavailability ~20-fold (2000%) compared to curcumin alone. The effect is real and has been broadly replicated. Important caveats: (1) The baseline is very low — unenhanced curcumin has dismal oral absorption (<5%), so a 20-fold increase still produces modest absolute plasma levels; (2) The effect is compound-specific — piperine raises curcumin bioavailability dramatically because curcumin is limited by UGT-mediated Phase II conjugation, which piperine inhibits. For resveratrol, quercetin, and EGCG, the effect is more modest (~2-4 fold); (3) Alternative enhanced curcumin formulations (Meriva phytosome, Longvida SLCP, Theracurmin nanoparticle, BCM-95) achieve enhanced bioavailability through formulation chemistry rather than piperine co-administration, and may produce comparable tissue exposure without the drug-interaction concerns of piperine. Practical bottom line: if you're using plain curcumin powder or standard curcumin capsules, piperine adds real value. If you're using an already-enhanced formulation, added piperine may be redundant.
What's the difference between Bioperine and black pepper extract?
Bioperine is a trademarked, proprietary black pepper extract from Sabinsa Corporation (established 1996), standardized to ≥95% piperine content with consistent quality control across batches. It has the most extensive clinical evidence base of any commercial piperine product and is the form used in most published bioavailability-enhancement studies. 'Black pepper extract' without standardization can mean anything from ~5% piperine (lightly extracted) to ~95% (nearly pure), and clinical effects scale directly with actual piperine content. Practical recommendation: choose products that either specify Bioperine (with the trademark) or state ≥95% piperine standardization with milligram content per serving. Avoid products that simply list 'black pepper extract' or 'contains piperine' without quantifying the content. Bioperine costs slightly more but has the most reliable formulation consistency — this matters because you're using piperine for its specific pharmacological effect (CYP3A4, P-gp, UGT inhibition), which requires reliable dose delivery.
Is it dangerous to take piperine with my statin?
It can be — yes, this is a real concern. Most statins (particularly simvastatin, atorvastatin, lovastatin) are metabolized by CYP3A4, and piperine inhibits CYP3A4. This can raise statin plasma levels, increasing the risk of muscle pain (myalgia), muscle inflammation (myositis), and — rarely — rhabdomyolysis (severe muscle breakdown). Case reports of piperine or Bioperine supplements contributing to statin-associated muscle symptoms exist in the literature. What to do if you're on a CYP3A4-sensitive statin: (1) Discuss piperine (including any Bioperine-containing product like curcumin+Bioperine) with your prescribing physician; (2) Monitor for new muscle pain or weakness after starting piperine; (3) A baseline and follow-up creatine kinase (CK) lab can quantify muscle effects if concerns arise; (4) Consider alternatives — rosuvastatin and pravastatin are less CYP3A4-dependent and have lower interaction risk, so a statin switch may be an option if piperine-containing supplements are important to your regimen. Bottom line: 'a little black pepper extract in my curcumin' is not pharmacologically trivial when combined with a statin. This is the classic example of a real drug-supplement interaction that is routinely overlooked.
How much piperine is too much?
For healthy adults without medication interactions, doses up to 20mg per dose (40mg/day) are well-characterized and generally well-tolerated. Above 40mg/day, GI side effects (heartburn, reflux, nausea) become more common, and the CYP3A4 inhibition intensifies — which is only relevant if you're on prescription medications but becomes more consequential if you are. Most evidence-based bioavailability-enhancement protocols use 5-20mg per dose, matching the Shoba 1998 curcumin protocol. Hidden exposure: many commercial polyphenol supplements include 5-10mg Bioperine bundled. If you take multiple such products (curcumin+Bioperine, quercetin+Bioperine, standalone piperine), total daily exposure can easily reach 30-50mg without your explicitly noticing. Audit your labels. Practical rule: 5-20mg/dose with the target compound you're enhancing, once or twice daily, with food. No ceiling benefit above 20mg/dose for most purposes. Avoid standalone piperine without a specific enhancement target — the direct effects of piperine (thermogenesis, mild anti-inflammatory) are not strong enough to justify its use outside the bioavailability-enhancement context.
Can piperine cause heartburn?
Yes, at higher doses — and it's the most common direct side effect. Piperine activates TRPV1 (the same receptor activated by capsaicin in chili peppers), which in the esophagus and upper GI tract can produce burning sensation, heartburn, reflux, and epigastric discomfort. At typical supplement doses (5-10mg) with food, these effects are uncommon. At higher doses (≥20mg) or on an empty stomach, they are more frequent. Mitigation: (1) Take with food, not on an empty stomach; (2) Take with a full glass of water; (3) Avoid lying down for 60-90 minutes after dosing; (4) Reduce dose or split across multiple smaller doses; (5) If persistent, discontinue. Pre-existing GERD, peptic ulcer disease, or esophagitis is a relative contraindication for higher-dose piperine — these patients should use lower doses or avoid standardized supplement forms (culinary black pepper is usually fine). If heartburn is severe or persistent, piperine is not the right supplement for you; most bioavailability-enhancement goals can be achieved with alternative formulations (phytosomal curcumin, quercetin phytosome, etc.) that don't require piperine.
Does piperine help you lose weight?
Not meaningfully. Piperine has been studied for thermogenic and weight-management effects, and rodent studies have shown inhibition of adipocyte differentiation and reduced fat accumulation. In humans, a single 20mg dose of piperine produces small but measurable increases in thermogenesis (~3-8%), and some small trials have shown modest metabolic effects. However: (1) The effect size is small and not reliably translated to meaningful weight loss; (2) Rodent studies use doses much higher than typical human supplement doses; (3) No rigorous long-term human RCT has established piperine as an effective weight-loss agent; (4) Commercial 'fat burner' stacks combining piperine with caffeine, green tea extract, and capsaicin may have additive thermogenic effects, but piperine is usually a minor contributor. Bottom line: piperine is not a weight-loss tool. Its value in metabolic stacks is primarily via enhancing bioavailability of other compounds — curcumin, berberine, and polyphenols with metabolic effects — rather than through its own thermogenic activity. If weight management is the primary goal, foundational interventions (caloric regulation, protein adequacy, resistance training, sleep, stress management) vastly outweigh any piperine contribution.
Should I take piperine every day or cycle it?
For bioavailability enhancement of a chronic-use target compound (daily curcumin, daily quercetin, daily resveratrol), continuous daily piperine dosing at 5-20mg with the target is the evidence-supported approach. Match your piperine schedule to the target compound's schedule — taking them hours apart reduces the enhancement effect. For pulse senolytic protocols (quercetin + fisetin 2-3 consecutive days monthly), use piperine 10-20mg only on pulse days. No strong evidence supports cycling (e.g., 5-on-2-off, 4-weeks-on-1-week-off) for general piperine use. Chronic daily dosing at typical supplement doses appears well-tolerated in healthy adults, with no evidence of tolerance, tachyphylaxis, or accumulation-related toxicity. Some cautious users cycle anyway — reasonable as a precaution but not evidence-based. Practical recommendation: if you're taking curcumin daily, take curcumin+piperine daily. If you're pulsing senolytics monthly, pulse piperine accordingly. Don't complicate the regimen with arbitrary cycling unless you have a specific reason.
Is piperine safe during pregnancy?
Dietary black pepper in food is fine during pregnancy — it's a normal culinary ingredient and poses no specific pregnancy risk at normal dietary exposure. Standardized piperine supplements are not recommended during pregnancy, for two reasons: (1) Rodent reproductive-toxicity signals — high-dose piperine in animal studies has shown adverse reproductive outcomes (fetal resorption, developmental effects), though the doses used were much higher than typical human supplement doses; (2) Drug-interaction amplification during pregnancy — hormonal and metabolic changes during pregnancy already alter drug disposition, and adding CYP3A4 inhibition (piperine) on top of pregnancy's own altered pharmacokinetics compounds unpredictability. Practical guidance: during pregnancy, discontinue any standardized piperine supplements (including curcumin+Bioperine products), and rely on culinary black pepper in food for normal dietary exposure. If a curcumin or quercetin supplement is important to you during pregnancy, choose a piperine-free formulation (Meriva phytosome curcumin, quercetin phytosome) — these achieve enhanced bioavailability through formulation chemistry without piperine co-administration. Breastfeeding: similar guidance — dietary pepper is fine, supplemental piperine is better avoided without obstetrician/pediatrician input. Not medical advice; pregnancy-specific decisions warrant obstetrician involvement.
Can I just eat more black pepper instead of taking Bioperine?
For general health and mild incidental exposure, yes — for specific clinical bioavailability enhancement, generally no. Whole black pepper contains piperine at roughly 3-9% by weight, meaning a typical dietary serving delivers 1-10mg piperine with wide variability depending on grind size, freshness, cooking method, and co-ingested food matrix. Culinary use advantages: cheap, universally available, safe, culturally normalized, provides flavor benefits, delivers mild incidental bioavailability enhancement for co-ingested spices and compounds (part of why traditional Indian and Ayurvedic cooking combines black pepper with turmeric in virtually every dish). Culinary use limitations: dose is inconsistent and usually too low for the ~20mg clinical bioavailability-enhancement threshold; piperine absorption from whole pepper is more variable than from standardized extract; matching piperine to a specific target compound's dosing is harder. Practical recommendation: for everyday dietary use, black pepper in cooking is great — add turmeric to your diet, cook with black pepper, use pepper liberally. For specific clinical bioavailability enhancement (when taking a supplement like curcumin 1-2g daily), standardized Bioperine 5-20mg per dose is more reliable. Both approaches are mechanistically valid; they're at different ends of the dose-reliability spectrum.
What's the deal with piperine and CYP3A4 — should I be worried?
Yes — but the concern is proportional to your prescription medication use, not to piperine itself. CYP3A4 is the cytochrome P450 enzyme that metabolizes roughly 50% of all prescription drugs. Piperine inhibits CYP3A4 through both reversible and mechanism-based (suicide) inhibition — and the mechanism-based component means CYP3A4 activity takes 24-48 hours to recover after the last piperine dose. Clinical implications: (1) If you're healthy, on no prescription medications, taking piperine 5-20mg daily for curcumin enhancement — CYP3A4 inhibition is not a problem. Piperine is mild relative to prescription CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir); (2) If you're on any CYP3A4-metabolized prescription drug (statins, calcium-channel blockers, benzodiazepines, immunosuppressants, HIV protease inhibitors, anticoagulants, many antidepressants, anticonvulsants, opioids, anticancer agents), piperine can raise that drug's plasma level and intensify effects — sometimes meaningfully; (3) The interaction is not eliminated by spacing — mechanism-based CYP3A4 inhibition persists 24-48 hours, so timing separation doesn't reliably avoid it. Practical recommendation: review your prescription medications (a pharmacist can do this in 5 minutes) before starting piperine. If on any high-interaction-risk drug (narrow-therapeutic-index, CYP3A4-sensitive), either choose a piperine-free alternative (phytosomal curcumin, etc.) or discuss piperine with your prescribing physician. For most healthy adults with no or minimal prescription use, piperine is safe and its CYP3A4 effect is clinically trivial. Piperine is not inert — but it's also not dangerous when used appropriately.
Research Tools
Related Compounds
View AllBeta-Sitosterol
HerbalPreclinicalBeta-sitosterol (β-sitosterol) is the most abundant plant sterol in human diets and nature, structurally similar to cholesterol but with an ethyl group addition at C-24 position, making it a phytosterol rather than a zoosterol.
Boswellia
HerbalPreclinicalBoswellia — the aromatic gum resin of the tree Boswellia serrata, known in Ayurvedic tradition as Shallaki or Salai guggul and in English as Indian frankincense — is one of the best-characterized non-NSAID anti-inflammatory botanicals in the modern clinical literature, and one of the few whose mechanism is sufficiently well-understood at the molecular level to justify most of its clinical positioning.
Comfrey
HerbalPreclinicalComfrey (Symphytum officinale) is one of the most mechanistically interesting — and simultaneously one of the most legally and toxicologically constrained — herbs in traditional European medicine.
Grape Seed Extract
HerbalPreclinicalGrape Seed Extract (GSE) — the lipid-soluble polyphenol-rich concentrate derived from the seeds of the common wine grape (Vitis vinifera, family Vitaceae) — is one of the most widely sold, most extensively researched, and most commercially heterogeneous botanical antioxidant products in the global supplement market.
Maitake
HerbalPreclinicalMaitake (Grifola frondosa) is a large, fan-shaped polypore fungus native to the temperate hardwood forests of Japan, China, Korea, and parts of northeastern North America and Europe.
Pygeum
HerbalPreclinicalPygeum (Prunus africana, formerly classified as Pygeum africanum) is a lipophilic bark extract derived from the African cherry tree — a large, slow-growing evergreen hardwood species native to the mountainous forests of sub-Saharan Africa, from Cameroon and Kenya through Uganda, Tanzania, Ethiopia, Madagascar, and south to South Africa.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
